E-LIB Suche - Ergebnisse für: Spänkuch, Birgit

1

Survival of primary, but not of cancer cells after combined..:

Lange, Lisa ; Hemmerich, Peter ; Spänkuch, Birgit
Oncotarget. 6 (2015) 28 - p. 25801-25814 , 2015

Link: https://doi.org/10.18632..

2

Combinatorial inhibition of Plk1 and PKCβ in cancer cells w..:

Lange, Lisa ; Keppner-Witter, Sarah ; Grigat, Juline.
Oncotarget. 5 (2014) 8 - p. 2263-2275 , 2014

Link: https://doi.org/10.18632..

3

Vanillin-derived antiproliferative compounds influence Plk1..:

Carrasco-Gomez, Roberto ; Keppner-Witter, Sarah ; Hieke, Martina...
Bioorganic & Medicinal Chemistry Letters. 24 (2014) 21 - p. 5063-5069 , 2014

Link: https://doi.org/10.1016/..

4

Wirkstoffe nach Zahlen: reaktionsbasierter De-novo-Entwurf ..:

Spänkuch, Birgit ; Keppner, Sarah ; Lange, Lisa...
Angewandte Chemie. 125 (2012) 17 - p. 4774-4779 , 2012

Link: https://doi.org/10.1002/..

5

Drugs by Numbers: Reaction‐Driven De Novo Design of Potent ..:

Spänkuch, Birgit ; Keppner, Sarah ; Lange, Lisa...
Angewandte Chemie International Edition. 52 (2012) 17 - p. 4676-4681 , 2012

Link: https://doi.org/10.1002/..

6

Fate of primary cells at the G1/S boundary after polo-like ..:

Keppner, Sarah ; Proschak, Ewgenij ; Schneider, Gisbert.
Cell Cycle. 10 (2011) 4 - p. 708-720 , 2011

Link: https://doi.org/10.4161/..

7

Biological impact of freezing Plk1 in its inactive conforma..:

Keppner, Sarah ; Proschak, Ewgenij ; Kaufmann, Manfred...
Cell Cycle. 9 (2010) 4 - p. 761-774 , 2010

Link: https://doi.org/10.4161/..

8

Identification and Validation of a Potent Type II Inhibitor..:

Keppner, Sarah ; Proschak, Ewgenij ; Schneider, Gisbert.
ChemMedChem. 4 (2009) 11 - p. 1806-1809 , 2009

Link: https://doi.org/10.1002/..

9

Downregulation of Plk1 Expression By Receptor-Mediated Upta..:

Spänkuch, Birgit ; Steinhauser, Isabel ; Wartlick, Heidrun...
Neoplasia. 10 (2008) 3 - p. 223-234 , 2008

Link: https://doi.org/10.1593/..

10

Effect of trastuzumab-modified antisense oligonucleotide-lo..:

Steinhauser, Isabel M. ; Langer, Klaus ; Strebhardt, Klaus M..
Biomaterials. 29 (2008) 29 - p. 4022-4028 , 2008

Link: https://doi.org/10.1016/..

11

Trastuzumab-modified nanoparticles: Optimisation of prepara..:

Steinhauser, Isabel ; Spänkuch, Birgit ; Strebhardt, Klaus.
Biomaterials. 27 (2006) 28 - p. 4975-4983 , 2006

Link: https://doi.org/10.1016/..

12

Investigations on the inducible and endothelial nitric oxid..:

Loibl, Sibylle ; Bratengeier, Jutta ; Farines, Vincent...
Pathology - Research and Practice. 202 (2006) 1 - p. 1-7 , 2006

Link: https://doi.org/10.1016/..

13

Downregulation of Plk1 expression by receptor-mediated upta..:

Spänkuch, Birgit ; Steinhauser, Isabelle Marie ; Wartlick, Heidrun...
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/76344. , 2014

Link: http://publikationen.ub...

14

Tumour cell delivery of antisense oligonuclceotides by huma..:

Wartlick, Heidrun ; Spänkuch-Schmitt, Birgit ; Strebhardt, Klaus..
Journal of Controlled Release. 96 (2004) 3 - p. 483-495 , 2004

Link: https://doi.org/10.1016/..

15

Downregulation of Plk1 Expression By Receptor-Mediated Upta..:

Birgit Spänkuch ; Isabel Steinhauser ; Heidrun Wartlick...
http://www.sciencedirect.com/science/article/pii/S1476558608801194. , 2008

Link: https://doi.org/10.1593/..